School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.
Division of Gastroenterology and Hepatology, Queen Mary Hospital, and Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
J Ethnopharmacol. 2015 Dec 24;176:35-48. doi: 10.1016/j.jep.2015.10.028. Epub 2015 Oct 19.
The antineoplastic property of Coptidis Rhizoma and berberine was correlated with its traditional use of clearing internal fire, removing damp-heat and counteracting toxic pathogens.
The anti-tumor effect of Coptidis Rhizoma and berberine was extensively studied since our last comprehensive review in 2009. This study aims to summarize the recent updates and give rise to perspectives of Coptidis Rhizoma and berberine as potential novel antineoplastic agents.
Quality studies in recent 5 years were retrieved from PubMed, Medline and CNKI with keywords including Coptis, Coptidis Rhizoma, huanglian, berberine, tumor and cancer. Studies were focused on the pharmacological actions of Coptidis Rhizoma and berberine in cancer progression.
It was shown that Coptidis Rhizoma extract and berberine may repress tumor progression by regressing abnormal cell proliferation, arresting cell cycle and inducing cell death. Studies also highlighted the actions of Coptidis Rhizoma extract and berberine in inhibiting tumor cell invasion and angiogenesis, which in turn abolish cancer metastasis. Some studies have also been conducted to reveal the potential effect of Coptidis Rhizoma extract and berberine in regulating tumor stromal microenvironment, as well as in preventing carcinogenesis. Most of the results have been demonstrated with in vivo models, but results of high-quality clinical trials are not yet available. Unspecified cancer type and staging, fluctuated dose information and variants of targets across studies of berberine/ Coptidis Rhizoma impede their clinical use for cancer treatment.
Recent advances highlighted by this review may shed light on future direction of studies featuring Coptidis Rhizoma and berberine as novel antineoplastic agents, which should be repeatedly proven in future animal and clinical studies. Although more evidences on its specificity and clinical efficacy are necessary to support its clinical use, Coptidis Rhizoma and berberine are highly expected to be effective, safe and affordable treatments for cancer patients.
黄连和小檗碱的抗肿瘤特性与其清热燥湿、解毒祛邪的传统用途相关。
自 2009 年我们进行全面综述以来，黄连和小檗碱的抗肿瘤作用已得到广泛研究。本研究旨在总结最新进展，并探讨黄连和小檗碱作为潜在新型抗肿瘤药物的前景。
从 PubMed、Medline 和中国知网（CNKI）中检索近 5 年的高质量研究，检索词包括黄连、黄连、黄连素、肿瘤和癌症。研究重点关注黄连和小檗碱在癌症进展中的药理作用。
研究表明，黄连提取物和小檗碱可能通过抑制异常细胞增殖、阻止细胞周期和诱导细胞死亡来抑制肿瘤进展。研究还强调了黄连提取物和小檗碱抑制肿瘤细胞侵袭和血管生成的作用，从而阻止癌症转移。一些研究还揭示了黄连提取物和小檗碱在调节肿瘤基质微环境以及预防癌变方面的潜在作用。大多数结果都是通过体内模型证明的，但高质量的临床试验结果尚不可用。小檗碱/黄连的未指明癌症类型和分期、波动的剂量信息以及研究之间靶点的差异，阻碍了其在癌症治疗中的临床应用。
本综述强调的最新进展可能为以黄连和小檗碱为新型抗肿瘤药物的研究指明方向，未来还需要在动物和临床研究中反复验证。虽然需要更多关于其特异性和临床疗效的证据来支持其临床应用，但黄连和小檗碱有望成为癌症患者有效、安全且负担得起的治疗方法。
Zotero 插件